34 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 39 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 39 | Completed 34, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Parotitis: new trials by email Literature Review of Parotitis trials Research Report on Parotitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril) - Measles-Mumps-Rubella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 1200 | 2024-06-28 | 2026-01-08 |
| Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination MMR booster vaccination (as M-M-R-VaxPro) - Mumps, Measles | Phase 3 | Unknown | University of Zurich | 200 | 2023-12-01 | 2024-01-08 |
| Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11 Attenuated Mumps vaccine (KMB-17) in phase II and III, Placebo in phase II, Attenuated Mumps vaccine (KMB-17) in phase III - Epidemic Parotitis, Mumps | Phase 2 / Phase 3 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 11999 | 2020-10-12 | 2023-10-11 |
| Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants investigational live attenuated mumps vaccine, control live attenuated mumps vaccine - Mumps | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 1150 | 2016-01-01 | 2017-10-26 |
| Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Investigational live attenuated mumps vaccine, control live attenuated mumps vaccine - Mumps | Phase 3 | Completed | Sinovac Research and Development Co., Ltd. | 1140 | 2016-01-01 | 2021-10-01 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. MMR Bio-Manguinhos, MMR GlaxoSmithKline - Measles, Mumps | Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1560 | 2015-02-01 | 2016-07-11 |
| Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine | Phase 3 | Completed | GlaxoSmithKline | 1742 | 2014-08-25 | 2021-01-07 |
| Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine - Rubella, Mumps | Phase 3 | Completed | GlaxoSmithKline | 996 | 2014-07-01 | 2018-06-06 |
| Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Priorix, M-M-R II, Varivax - Rubella, Measles | Phase 3 | Completed | GlaxoSmithKline | 5016 | 2012-11-09 | 2019-11-25 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Priorix, M-M-R II, Varivax - Measles, Mumps | Phase 3 | Completed | GlaxoSmithKline | 4538 | 2012-10-10 | 2021-01-07 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Priorix, M-M-R II, Kinrix - Measles-Mumps-Rubella | Phase 3 | Completed | GlaxoSmithKline | 4011 | 2012-06-21 | 2019-11-25 |
| Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) MMRV (AMP), MMRV (2006 process) - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1412 | 2012-06-05 | 2018-10-31 |
| Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children PriorixTetra™, Meningitec - Rubella, Varicella | Phase 3 | Completed | GlaxoSmithKline | 716 | 2012-02-06 | 2018-08-17 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 542 | 2010-08-01 | 2014-08-15 |
| Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™ - Varicella, Rubella | Phase 3 | Completed | GlaxoSmithKline | 450 | 2009-11-09 | 2018-06-08 |
| Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 PriorixTM, VarilrixTM, Priorix-Tetra® - Measles, Varicella | Phase 3 | Completed | GlaxoSmithKline | 475 | 2008-10-01 | 2018-06-08 |
| A Study of ProQuad™ in Healthy Children in Korea (V221-023) Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™), M-M-R™ II and Varivax™ - Measles, Mumps | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 30 | 2008-02-01 | 2017-04-12 |
| Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers MenACWY-CRM + MMRV, MMRV, MenACWY-CRM - Meningococcal Infections | Phase 3 | Completed | Novartis Vaccines | 1630 | 2008-02-01 | 2013-04-19 |
Showing 20 of 39. Sign in to see all of them.
Mumps (39) · Measles (36) · Rubella (35) · Chickenpox (28) · Haemophilus Infections (4) · Meningitis, Meningococcal (3) · Diphtheria (1) · Encephalitis, Japanese (1) · Hepatitis B (1) · Meningitis (1) · Meningococcal Infections (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Infections (39) · Mononegavirales Infections (39) · Mouth Diseases (39) · Paramyxoviridae Infections (39) · Parotid Diseases (39) · RNA Virus Infections (39) · Rubulavirus Infections (39) · Salivary Gland Diseases (39) · Stomatognathic Diseases (39) · Virus Diseases (39) · Morbillivirus Infections (36) · Rubivirus Infections (35) · Togaviridae Infections (35) · DNA Virus Infections (28)
measles, mumps, rubella, varicella vaccine (18) · Measles-Mumps-Rubella Vaccine (8) · Chickenpox Vaccine (6) · Hepatitis A Vaccines (4) · Rubella Vaccine (4) · 13-valent pneumococcal vaccine (3) · Meningococcal Vaccines (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · DTPP vaccine (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Vaccines (2) · Vaccines, Attenuated (2) · Adenosine Monophosphate (1) · Clinical Trials, Phase II as Topic (1) · Clinical Trials, Phase III as Topic (1)
GlaxoSmithKline (14) · Merck Sharp & Dohme LLC (14) · Sanofi Pasteur, a Sanofi Company (4) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Novartis Vaccines (1) · Shanghai Institute Of Biological Products (1) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (1) · Sinovac Research and Development Co., Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · University of Zurich (1)
United States (11) · Germany (6) · Puerto Rico (5) · Finland (4) · Taiwan (4) · China (3) · Estonia (3) · Italy (3) · South Korea (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1)
Jingchen Ma (2) · Anne Fiquet, MD (1) · Eliane Matos Santos (1) · Jan Fehr, M.D. (1) · Qihan Li (1) · Walter Otieno, Doctor (1)
PMID 16452343, PMID 16567978, PMID 16804432, PMID 17502347, PMID 19366435, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 29902133, PMID 30481110
2025 (2)